{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:53:36Z","timestamp":1774317216581,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to environmental\/occupational exposure to asbestos, characterized by the presence of significant areas of hypoxia. In this study, we firstly explored the expression and the role of transglutaminase 2 (TG2) in MPM cell adaptation to hypoxia. We demonstrated that cells derived from biphasic MPM express the full-length TG2 variant at higher levels than cells derived from epithelioid MPM and normal mesothelium. We observed a significant induction of TG2 expression and activity when cells from biphasic MPM were grown as a monolayer in chronic hypoxia or packed in spheroids, where the presence of a hypoxic core was demonstrated. We described that the hypoxic induction of TG2 was HIF-2 dependent. Importantly,<jats:italic>TGM2-v1<\/jats:italic>silencing caused a marked and significant reduction of MPM cell viability in hypoxic conditions when compared with normoxia. Notably, a TG2-selective irreversible inhibitor that reacts with the intracellular active form of TG2, but not a non-cell-permeable inhibitor, significantly compromised cell viability in MPM spheroids. Understanding the expression and function of TG2 in the adaptation to the hypoxic environment may provide useful information for novel promising therapeutic options for MPM treatment.<\/jats:p>","DOI":"10.1038\/cddis.2017.30","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T13:45:39Z","timestamp":1486043139000},"page":"e2592-e2592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia"],"prefix":"10.1038","volume":"8","author":[{"given":"Sara","family":"Zonca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Felicia","family":"Soluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Tavian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Sblattero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"key":"BFcddis201730_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/107327480601300402","volume":"13","author":"R Ismail-Khan","year":"2006","unstructured":"Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR . Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006; 13: 255\u2013263.","journal-title":"Cancer Control"},{"key":"BFcddis201730_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA, Kindler HL . Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081\u20132090.","journal-title":"J Clin Oncol"},{"key":"BFcddis201730_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/oemed-2015-103074","volume":"73","author":"C Gilham","year":"2016","unstructured":"Gilham C, Rake C, Burdett G, Nicholson AG, Davison L, Franchini A et al. Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med 2016; 73: 290\u2013299.","journal-title":"Occup Environ Med"},{"key":"BFcddis201730_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/1753465816628800","volume":"10","author":"S Kondola","year":"2016","unstructured":"Kondola S, Manners D, Nowak AK . Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis 2016; 10: 275\u2013288.","journal-title":"Ther Adv Respir Dis"},{"key":"BFcddis201730_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636\u20132644.","journal-title":"J Clin Oncol"},{"key":"BFcddis201730_CR6","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP Van Meerbeeck","year":"2005","unstructured":"Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881\u20136889.","journal-title":"J Clin Oncol"},{"key":"BFcddis201730_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/17476348.2015.1083426","volume":"9","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, Kelany M . Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Rev Respir Med 2015; 9: 533\u2013549.","journal-title":"Expert Rev Respir Med"},{"key":"BFcddis201730_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrm1014","volume":"4","author":"L Lorand","year":"2003","unstructured":"Lorand L, Graham RM . Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003; 4: 140\u2013156.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddis201730_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbamcr.2011.09.012","volume":"1823","author":"S Gundemir","year":"2012","unstructured":"Gundemir S, Colak G, Tucholski J, Johnson GV . Transglutaminase 2: molecular Swiss army knife. Biochim Biophys Acta 2012; 1823: 406\u2013419.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis201730_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.bbabio.2006.07.007","volume":"1757","author":"PG Mastroberardino","year":"2006","unstructured":"Mastroberardino PG, Farrace MG, Viti I, Pavone F, Fimia GM, Melino G et al. \u2018Tissue\u2019 transglutaminase contributes to the formation of disulphide bridges in proteins of mitochondrial respiratory complexes. Biochim Biophys Acta 2006; 1757: 1357\u20131365.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis201730_CR11","doi-asserted-by":"publisher","first-page":"23863","DOI":"10.1074\/jbc.M311919200","volume":"279","author":"S Mishra","year":"2004","unstructured":"Mishra S, Murphy LJ . Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 2004; 279: 23863\u201323868.","journal-title":"J Biol Chem"},{"key":"BFcddis201730_CR12","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1074\/jbc.M506864200","volume":"281","author":"S Mishra","year":"2006","unstructured":"Mishra S, Saleh A, Espino PS, Davie JR, Murphy LJ . Phosphorylation of histones by tissue transglutaminase. J Biol Chem 2006; 281: 5532\u20135538.","journal-title":"J Biol Chem"},{"key":"BFcddis201730_CR13","doi-asserted-by":"publisher","first-page":"40212","DOI":"10.1074\/jbc.M110.123703","volume":"285","author":"Z Wang","year":"2010","unstructured":"Wang Z, Collighan RJ, Gross SR, Danen EH, Orend G, Telci D et al. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4\/2 and \u03b15\u03b21 integrin co-signalling. J Biol Chem 2010; 285: 40212\u201340229.","journal-title":"J Biol Chem"},{"key":"BFcddis201730_CR14","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1242\/jcs.114.16.2989","volume":"114","author":"SS Akimov","year":"2001","unstructured":"Akimov SS, Belkin AM . Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition. J Cell Sci 2001; 114: 2989\u20133000.","journal-title":"J Cell Sci"},{"key":"BFcddis201730_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11010-009-0252-9","volume":"335","author":"JM Schmitt","year":"2010","unstructured":"Schmitt JM, Abell E, Wagner A, Davare MA . ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells. Mol Cell Biochem 2010; 335: 155\u2013171.","journal-title":"Mol Cell Biochem"},{"key":"BFcddis201730_CR16","doi-asserted-by":"publisher","first-page":"e74437","DOI":"10.1371\/journal.pone.0074437","volume":"8","author":"J Assi","year":"2013","unstructured":"Assi J, Srivastava G, Matta A, Chang MC, Walfish PG, Ralhan R . Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence. PloS One 2013; 8: e74437.","journal-title":"PloS One"},{"key":"BFcddis201730_CR17","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/1078-0432.CCR-07-4529","volume":"14","author":"A Verma","year":"2008","unstructured":"Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G et al, Therapeutic significance of elevated tissue transglutaminase expression in pancreaticcancer. Clin Cancer Res 2008; 14: 2476\u20132483.","journal-title":"Clin Cancer Res"},{"key":"BFcddis201730_CR18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00726-010-0790-1","volume":"41","author":"P Kotsakis","year":"2011","unstructured":"Kotsakis P, Wang Z, Collighan RJ, Griffin M . The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26. Amino Acids 2011; 41: 909\u2013921.","journal-title":"Amino Acids"},{"key":"BFcddis201730_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3346\/jkms.2013.28.7.1005","volume":"28","author":"JH Jeong","year":"2013","unstructured":"Jeong JH, Cho BC, Shim HS, Kim HR, Lim SM, Kim SK et al. Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor. J Korean Med Sci 2013; 28: 1005\u20131014.","journal-title":"J Korean Med Sci"},{"key":"BFcddis201730_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/1535-7163.MCT-10-0912","volume":"10","author":"M Khanna","year":"2011","unstructured":"Khanna M, Chelladurai B, Gavini A, Li L, Shao M, Courtney D et al. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. Mol Cancer Ther 2011; 10: 626\u2013636.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis201730_CR21","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1038\/sj.onc.1209324","volume":"25","author":"JF Herman","year":"2006","unstructured":"Herman JF, Mangala LS, Mehta K . Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 2006; 25: 3049\u20133058.","journal-title":"Oncogene"},{"key":"BFcddis201730_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1152\/physrev.00019.2013","volume":"94","author":"RL Eckert","year":"2014","unstructured":"Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV et al. Transglutaminase regulation of cell function. Physiol Rev 2014; 94: 383\u2013417.","journal-title":"Physiol Rev"},{"key":"BFcddis201730_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00726-011-1167-9","volume":"44","author":"A Budillon","year":"2013","unstructured":"Budillon A, Carbone C, Di Gennaro E . Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids 2013; 44: 63\u201372.","journal-title":"Amino Acids"},{"key":"BFcddis201730_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/onc.2009.342","volume":"29","author":"GY Jang","year":"2010","unstructured":"Jang GY, Jeon JH, Cho SY, Shin DM, Kim CW, Jeong EM et al. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 2010; 29: 356\u2013367.","journal-title":"Oncogene"},{"key":"BFcddis201730_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","volume":"26","author":"P Vaupel","year":"2007","unstructured":"Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225\u2013239.","journal-title":"Cancer Metastasis Rev"},{"key":"BFcddis201730_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.semnuclmed.2014.11.002","volume":"45","author":"N Dhani","year":"2015","unstructured":"Dhani N, Fyles A, Hedley D, Milosevic M . The clinical significance of hypoxia in human cancers. Semin Nucl Med 2015; 45: 110\u2013121.","journal-title":"Semin Nucl Med"},{"key":"BFcddis201730_CR27","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL . Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510\u20135514.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis201730_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccr.2006.08.026","volume":"10","author":"L Holmquist-Mengelbier","year":"2006","unstructured":"Holmquist-Mengelbier L, Fredlund E, L\u00f6fstedt T, Noguera R, Navarro S, Nilsson H et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2\u03b1 promotes an aggressive phenotype. Cancer Cell 2006; 10: 413\u2013423.","journal-title":"Cancer Cell"},{"key":"BFcddis201730_CR29","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1158\/0008-5472.CAN-10-4142","volume":"71","author":"MY Koh","year":"2011","unstructured":"Koh MY, Lemos R Jr, Liu X, Powis G . The hypoxia-associated factor switches cells from HIF-1{alpha}- to HIF-2{alpha}-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 2011; 71: 4015\u20134027.","journal-title":"Cancer Res"},{"key":"BFcddis201730_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tibs.2012.06.004","volume":"37","author":"MY Koh","year":"2012","unstructured":"Koh MY, Powis G . Passing the baton: the HIF switch. Trends Biochem Sci 2012; 37: 364\u2013372.","journal-title":"Trends Biochem Sci"},{"key":"BFcddis201730_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lungcan.2015.07.015","volume":"90","author":"RJ Francis","year":"2015","unstructured":"Francis RJ, Segard T, Morandeau L, Lee YC, Millward MJ, Segal A et al. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. Lung Cancer 2015; 90: 55\u201360.","journal-title":"Lung Cancer"},{"key":"BFcddis201730_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00726-011-1127-4","volume":"44","author":"VM Phatak","year":"2013","unstructured":"Phatak VM, Croft SM, Rameshaiah Setty SG, Scarpellini A, Hughes DC, Rees R et al. Expression of transglutaminase-2 isoforms in normal human tissues and cancer cell lines: dysregulation of alternative splicing in cancer. Amino Acids 2013; 44: 33\u201344.","journal-title":"Amino Acids"},{"key":"BFcddis201730_CR33","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-12-0858","volume":"18","author":"TW Meijer","year":"2012","unstructured":"Meijer TW, Kaanders JH, Span PN, Bussink J . Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 2012; 18: 5585\u20135594.","journal-title":"Clin Cancer Res"},{"key":"BFcddis201730_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1367","volume":"4","author":"JM Brown","year":"2004","unstructured":"Brown JM, Wilson WR . Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437\u2013447.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis201730_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.biotechadv.2016.04.005","volume":"34","author":"A Patel","year":"2016","unstructured":"Patel A, Sant S . Hypoxic tumor microenvironment: opportunities to develop targeted therapies. Biotechnol Adv 2016; 34: 803\u2013812.","journal-title":"Biotechnol Adv"},{"key":"BFcddis201730_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza GL . Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721\u2013732.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis201730_CR37","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.2174\/0929867321666140414101056","volume":"21","author":"NA Warfel","year":"2014","unstructured":"Warfel NA, El-Deiry WS . HIF-1 signaling in drug resistance to chemotherapy. Curr Med Chem 2014; 21: 3021\u20133028.","journal-title":"Curr Med Chem"},{"key":"BFcddis201730_CR38","doi-asserted-by":"publisher","first-page":"25121","DOI":"10.18632\/oncotarget.4486","volume":"6","author":"AG Manente","year":"2015","unstructured":"Manente AG, Pinton G, Zonca S, Cilli M, Rinaldi M, Daga A et al. Intracellular lactate-mediated induction of estrogen receptor beta (ER\u03b2 in biphasic malignant pleural mesothelioma cells. Oncotarget 2015; 6: 25121\u201325134.","journal-title":"Oncotarget"},{"key":"BFcddis201730_CR39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00726-011-1008-x","volume":"42","author":"Z Wang","year":"2012","unstructured":"Wang Z, Griffin M . TG2, a novel extracellular protein with multiple functions. Amino Acids 2012; 42: 939\u2013949.","journal-title":"Amino Acids"},{"key":"BFcddis201730_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-394305-7.00001-X","volume":"294","author":"MV Nurminskaya","year":"2012","unstructured":"Nurminskaya MV, Belkin AM . Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol 2012; 294: 1\u201397.","journal-title":"Int Rev Cell Mol Biol"},{"key":"BFcddis201730_CR41","first-page":"2756","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Xu AM, Liu W . Transglutaminase 2 in cancer. Am J Cancer Res 2015; 5: 2756\u20132776.","journal-title":"Am J Cancer Res"},{"key":"BFcddis201730_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gde.2009.10.009","volume":"20","author":"GL Semenza","year":"2010","unstructured":"Semenza GL . HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51\u201356.","journal-title":"Curr Opin Genet Dev"},{"key":"BFcddis201730_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/9781118105771.ch1","volume":"78","author":"CM Bergamini","year":"2011","unstructured":"Bergamini CM, Collighan RJ, Wang Z, Griffin M . Structure and regulation of type 2 transglutaminase in relation to its physiological functions and pathological roles. Adv Enzymol Relat Areas Mol Biol 2011; 78: 1\u201346.","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"BFcddis201730_CR44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ejmech.2013.05.018","volume":"66","author":"E Badarau","year":"2013","unstructured":"Badarau E, Mongeot A, Collighan RJ, Rathbone DL, Griffin M . Imidazolium-based warheads strongly influence activity of water-soluble peptidic transglutaminase inhibitors. Eur J Med Chem 2013; 66: 526\u2013530.","journal-title":"Eur J Med Chem"},{"key":"BFcddis201730_CR45","doi-asserted-by":"crossref","first-page":"20525","DOI":"10.18632\/oncotarget.3890","volume":"6","author":"ML Fisher","year":"2015","unstructured":"Fisher ML, Adhikary G, Xu W, Kerr C, Keillor JW, Eckert RL . Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition. Oncotarget 2015; 6: 20525\u201320539.","journal-title":"Oncotarget"},{"key":"BFcddis201730_CR46","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1186\/bcr3085","volume":"14","author":"A Kumar","year":"2012","unstructured":"Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB et al. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 2012; 14: R4.","journal-title":"Breast Cancer Res"},{"key":"BFcddis201730_CR47","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chembiol.2015.08.013","volume":"22","author":"E Badarau","year":"2015","unstructured":"Badarau E, Wang Z, Rathbone DL, Costanzi A, Thibault T, Murdoch CE et al. Development of potent and selective tissue transglutaminase inhibitors: their effect on TG2 function and application in pathological conditions. Chem Biol 2015; 22: 1347\u20131361.","journal-title":"Chem Biol"},{"key":"BFcddis201730_CR48","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1016\/j.bmcl.2008.09.006","volume":"18","author":"M Griffin","year":"2008","unstructured":"Griffin M, Mongeot R, Collighan R, Saint RE, Jones RA, Coutts IG et al. Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett 2008; 18: 5559\u20135562.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFcddis201730_CR49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7150\/jca.2.507","volume":"2","author":"YT Phung","year":"2011","unstructured":"Phung YT, Barbone D, Broaddus VC, Ho M . Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy. J Cancer 2011; 2: 507\u2013514.","journal-title":"J Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis201730.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis201730","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis201730.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T01:36:13Z","timestamp":1692668173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis201730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]}},"alternative-id":["BFcddis201730"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2017.30","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]},"assertion":[{"value":"20 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}